- Home
- PIII vs SLGL Comparison
PIII vs SLGL Comparison
Compare PIII & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | SLGL |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Israel |
| Employees | 360 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 247.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PIII | SLGL |
|---|---|---|
| Price | $2.70 | $77.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.25 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 100.9K | 10.2K |
| Earning Date | 03-26-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.40 |
| 52 Week High | $11.30 | $97.97 |
Technical Indicators
Market Signals| Indicator | PIII | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 46.35 |
| Support Level | $1.52 | $71.01 |
| Resistance Level | $2.85 | $96.99 |
| Average True Range (ATR) | 0.53 | 10.88 |
| MACD | 0.02 | -2.20 |
| Stochastic Oscillator | 30.30 | 15.17 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.